ArticleFrontiers in neurology2017

Chronic 5-Aminoimidazole-4-Carboxamide-1-β-d-Ribofuranoside Treatment Induces Phenotypic Changes in Skeletal Muscle, but Does Not Improve Disease Outcomes in the R6/2 Mouse Model of Huntington's Disease.

Marie-France Paré et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.